title: Hematopoietic turnover index in reactive and neoplastic bone marrow lesions: quantification by apoptosis and PCNA labeling.
abstract: In order to determine the dynamics of hematopoietic cell turnover, proliferative activity and incidence of apoptosis (programmed cell death) were evaluated in bone marrow trephine biopsies. Selection of patients (20 in each group) included in addition to a control group, idiopathic thrombocytopenia (ITP), reactive thrombocytosis (TH), secondary polycythemia-smokers' polyglobuly (PG), primary (essential-hemorrhagic) thrombocythemia (PTH), polycythemia vera (PV), and finally acute myeloid leukemia (AML). Apoptosis was demonstrated by the in situ end-labeling technique (ISEL) and proliferative activity by applying the monoclonal antibody PC10 raised against proliferating cell nuclear antigen (PCNA). To assess dynamic features of hematopoiesis, an index was calculated consisting of the ratio between PCNA-positive nuclei and the apoptotic cell fraction. This factor was termed the hematopoietic turnover index (HTI). Morphometric analysis revealed that the HTI was significantly increased in AML and PV. According to cell culture studies both disorders are characterized by either a prevalent proliferation of the myeloid or erythroid cell mass. On the other hand, PG, PTH, and TH showed no relevant enhancement of this index in comparison to the control specimen. In vitro experiment results are in keeping with the finding that PG and PTH are not associated with a significant expansion of the erythroid lineage (CFU-E). Similar to ITP and TH, in PTH megakaryocyte proliferation (CFU-MEG) is the predominant feature of cell turnover. Differences between PTH and TH are in line with the reduced in vitro formation of CFU-MEG in the latter disorder. In conclusion, our in situ study on turnover rates of the bone marrow in various neoplastic and reactive lesions extends previous experimental data on hematopoietic cell kinetics.
authors.affiliation: Institute of Pathology, University of Cologne, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Thiele
authors.forename: T K
authors.initials: TK
authors.lastname: Zirbes
authors.forename: J
authors.initials: J
authors.lastname: Lorenzen
authors.forename: H M
authors.initials: HM
authors.lastname: Kvasnicka
authors.forename: S
authors.initials: S
authors.lastname: Scholz
authors.forename: A
authors.initials: A
authors.lastname: Erdmann
authors.forename: U
authors.initials: U
authors.lastname: Flucke
authors.forename: V
authors.initials: V
authors.lastname: Diehl
authors.forename: R
authors.initials: R
authors.lastname: Fischer
mesh_terms: D000208:Acute Disease; D000951:Antigens, Neoplasm / Q000032:analysis; D017209:Apoptosis; D001855:Bone Marrow Diseases / Q000503:physiopathology*; D019046:Bone Marrow Neoplasms / Q000503:physiopathology; D006410:Hematopoiesis; D006801:Humans; D007951:Leukemia, Myeloid / Q000503:physiopathology; D011086:Polycythemia / Q000503:physiopathology; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D013921:Thrombocytopenia / Q000503:physiopathology; D013922:Thrombocytosis / Q000503:physiopathology
chemical_list: D000951:Antigens, Neoplasm; D018809:Proliferating Cell Nuclear Antigen